stockrowPacira BioSciences, Inc. (PCRX) vs Xeris Biopharma Holdings, Inc. (XERS)
- Pacira BioSciences, Inc. PCRX 36.44 +0.11%
- Xeris Biopharma Holdings, Inc. XERS 12.95 +23.80%
Pacira BioSciences, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $2.4B against $1.5B — 1.6× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Pacira BioSciences, Inc. trades at 38.4×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 38.4% against 3.70%. Pacira BioSciences, Inc. has the higher net margin (5.08% vs −1.76%) and the lower return on invested capital (5.37% vs 27.2%). Across the 21 metrics below, Pacira BioSciences, Inc. leads on 15 and Xeris Biopharma Holdings, Inc. on 6.
Valuation
Profitability
| Metric | PCRX | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 0.00% | 87.38% | 53.51% |
| Operating margin | 4.81% | 12.70% | 0.00% |
| Net margin | 5.08% | (1.76%) | (2.45%) |
| Free cash flow margin | 22.74% | 20.00% | 0.00% |
| Return on equity | 5.24% | (27.11%) | (0.80%) |
| Return on assets | 3.02% | (1.64%) | (1.67%) |
| Return on invested capital | 5.37% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack